We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Ligand Pharmaceuticals Inc (LGND) - Financial and Strategic SWOT Analysis Review

Published: July 2019
Pages: 63
Code: EEAD25CD5483747D46DB6AC04099C31D
Format: PDF
Publisher GlobalData
From Add to basket
$ 125.00
Provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

Additonal Information

  • - Business description – A detailed description of the company’s operations and business divisions.
  • - Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • - Company history – Progression of key events associated with the company.
  • - Major products and services – A list of major products, services and brands of the company.
  • - Key competitors – A list of key competitors to the company.
  • - Key employees – A list of the key executives of the company.
  • - Executive biographies – A brief summary of the executives’ employment history.
  • - Key operational heads – A list of personnel heading key departments/functions.
  • - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
  • Highlights
  • Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies that help biopharmaceutical companies in the discovery and development of medicines. Its major research technologies include nuclear receptor assays, formulation science, high throughput computer screening, antibody discovery technologies and liver targeted pro-drug technologies, which assist pharmaceutical companies in securing prescription drug approvals. Its technologies and research capabilities contributed the development of a diversified portfolio of biotechnology and pharmaceutical products for fungal infections, hepatitis C, Idiopathic thrombocytopenic purpura (ITP), multiple myeloma, cancer, osteoporosis, and severe aplastic anemia. Ligand also offers late-stage development, regulatory management and commercialization support in partnership with other pharmaceutical companies. Ligand is headquartered in San Diego, California, the US.
  • Ligand Pharmaceuticals Inc Key Recent Developments
  • May 02,2019: Ligand reports first quarter 2019 financial results
  • Mar 12,2019: Ligand provides highlights from Analyst Day Event
  • Mar 06,2019: Ligand divests Promacta rights to Royalty Pharma for $827m
  • Feb 07,2019: Ligand announces OmniAb partnership with Genagon Therapeutics
  • Feb 07,2019: Ligand reports fourth quarter and full year 2018 financial results

Companies Mentioned

Atara Biotherapeutics Inc
Amgen Inc
Gilead Sciences Inc
Alexion Pharmaceuticals Inc

Reasons to buy

You get detailed information about the company and its operations to identify potential customers and suppliers. The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors. Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted. Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios. Gain key insights into the company for academic or business research. Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. Note: Some sections may be missing if data is unavailable for the company
Add to basket
  • Table of Contents
  • Table of Contents
  • List of Tables
  • List of Figures
  • Section 1 - About the Company
  • Ligand Pharmaceuticals Inc - Key Facts
  • Ligand Pharmaceuticals Inc - Key Employees
  • Ligand Pharmaceuticals Inc - Key Employee Biographies
  • Ligand Pharmaceuticals Inc - Major Products and Services
  • Ligand Pharmaceuticals Inc - History
  • Ligand Pharmaceuticals Inc - Company Statement
  • Ligand Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Section 2 – Company Analysis
  • Company Overview
  • Ligand Pharmaceuticals Inc - Business Description
  • Ligand Pharmaceuticals Inc - Corporate Strategy
  • Ligand Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Ligand Pharmaceuticals Inc - Strengths
  • Ligand Pharmaceuticals Inc - Weaknesses
  • Ligand Pharmaceuticals Inc - Opportunities
  • Ligand Pharmaceuticals Inc - Threats
  • Ligand Pharmaceuticals Inc - Key Competitors
  • Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
  • Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
  • Ligand Pharmaceuticals Inc, Recent Deals Summary
  • Section 5 – Company’s Recent Developments
  • May 02, 2019: Ligand reports first quarter 2019 financial results
  • Mar 12, 2019: Ligand provides highlights from Analyst Day Event
  • Mar 06, 2019: Ligand divests Promacta rights to Royalty Pharma for $827m
  • Feb 07, 2019: Ligand announces OmniAb partnership with Genagon Therapeutics
  • Feb 07, 2019: Ligand reports fourth quarter and full year 2018 financial results
  • Dec 18, 2018: Ligand introduces 2019 financial outlook and raises 2018 financial guidance
  • Nov 08, 2018: Ligand reports third quarter 2018 financial results
  • Aug 06, 2018: Ligand reports second quarter 2018 financial results
  • Jul 27, 2018: Fr. Emmanuel Lemelson Responds to SEC Charges
  • May 08, 2018: Ligand Reports First Quarter 2018 Financial Results May 8, 2018
  • Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About GlobalData
  • Contact Us
  • Disclaimer
  • List of Tables
  • Ligand Pharmaceuticals Inc, Key Facts
  • Ligand Pharmaceuticals Inc, Key Employees
  • Ligand Pharmaceuticals Inc, Key Employee Biographies
  • Ligand Pharmaceuticals Inc, Major Products and Services
  • Ligand Pharmaceuticals Inc, History
  • Ligand Pharmaceuticals Inc, Subsidiaries
  • Ligand Pharmaceuticals Inc, Key Competitors
  • Ligand Pharmaceuticals Inc, Ratios based on current share price
  • Ligand Pharmaceuticals Inc, Annual Ratios
  • Ligand Pharmaceuticals Inc, Annual Ratios (Cont...1)
  • Ligand Pharmaceuticals Inc, Annual Ratios (Cont...2)
  • Ligand Pharmaceuticals Inc, Interim Ratios
  • Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
  • Ligand Pharmaceuticals Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
  • List of Figures
  • Ligand Pharmaceuticals Inc, Performance Chart (2014 - 2018)
  • Ligand Pharmaceuticals Inc, Ratio Charts
  • Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

Keywords
;